Short Term Rating on Keryx Biopharmaceuticals (KERX)

Keryx Biopharmaceuticals (KERX) : Zacks Investment Research ranks Keryx Biopharmaceuticals (KERX) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.56, which indicates as a Buy.

Keryx Biopharmaceuticals (KERX) : The highest short term price target forecast on Keryx Biopharmaceuticals (KERX) is $13 and the lowest target price is $4. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $9 with a standard deviation of $2.83.

For the current week, the company shares have a recommendation consensus of Buy.


Keryx Biopharmaceuticals (NASDAQ:KERX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.24 and $7.15 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.33. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.16, notching a gain of 0.28% for the day. The total traded volume was 1,072,386 . The stock had closed at $7.14 on the previous day.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.